# Tactile Systems Technology Inc: overview

TCMD · Nasdaq · CIK 1027838 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tcmd.md) · [Financials](/companies/tcmd/financials.md) · [Filings](/companies/tcmd/filings.md) · [Insiders](/companies/tcmd/insiders.md)

Latest reported revenue: [$85.7m](/filings/0001104659-26-093352.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-093352).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [73.1](/filings/0001104659-25-105543.md) | [85.6 d](/filings/0001104659-26-016380.md) | [61.3](/filings/0001104659-26-054877.md) | [78.9](/filings/0001104659-26-093352.md) | [85.8](/filings/0001104659-25-105543.md) | [104 d](/filings/0001104659-26-016380.md) | [75.3](/filings/0001104659-26-054877.md) | [85.7](/filings/0001104659-26-093352.md) |
| Gross margin | % | [75.0%](/filings/0001104659-25-105543.md) | [75.2% d](/filings/0001104659-26-016380.md) | [74.0%](/filings/0001104659-26-054877.md) | [74.5%](/filings/0001104659-26-093352.md) | [75.8%](/filings/0001104659-25-105543.md) | [78.2% d](/filings/0001104659-26-016380.md) | [76.5%](/filings/0001104659-26-054877.md) | [76.3%](/filings/0001104659-26-093352.md) |
| Operating margin | % | [9.3%](/filings/0001104659-25-105543.md) | [14.6% d](/filings/0001104659-26-016380.md) | [(7.4%)](/filings/0001104659-26-054877.md) | [5.2%](/filings/0001104659-26-093352.md) | [12.8%](/filings/0001104659-25-105543.md) | [18.1% d](/filings/0001104659-26-016380.md) | [(2.0%)](/filings/0001104659-26-054877.md) | [8.0%](/filings/0001104659-26-093352.md) |
| Net margin | % | [7.1%](/filings/0001104659-25-105543.md) | [11.4% d](/filings/0001104659-26-016380.md) | [(4.9%)](/filings/0001104659-26-054877.md) | [4.1%](/filings/0001104659-26-093352.md) | [9.6%](/filings/0001104659-25-105543.md) | [10.3% d](/filings/0001104659-26-016380.md) | [(2.3%)](/filings/0001104659-26-054877.md) | [9.1%](/filings/0001104659-26-093352.md) |
| Diluted EPS | $ per share | [0.21](/filings/0001104659-25-105543.md) | not reported | [(0.13)](/filings/0001104659-26-054877.md) | [0.14](/filings/0001104659-26-093352.md) | [0.36](/filings/0001104659-25-105543.md) | not reported | [(0.08)](/filings/0001104659-26-054877.md) | [0.34](/filings/0001104659-26-093352.md) |
| Free cash flow | $m | [9.3 d](/filings/0001104659-25-105543.md) | [15.9 d](/filings/0001104659-26-016380.md) | [0.0](/filings/0001104659-26-054877.md) | [14.4 d](/filings/0001104659-26-093352.md) | [9.2 d](/filings/0001104659-25-105543.md) | [16.8 d](/filings/0001104659-26-016380.md) | [(1.2)](/filings/0001104659-26-054877.md) | [2.0 d](/filings/0001104659-26-093352.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [208](/filings/0001558370-24-001330.md) | [247](/filings/0001558370-25-001096.md) | [274](/filings/0001104659-26-016380.md) | [293](/filings/0001104659-26-016380.md) | [330](/filings/0001104659-26-016380.md) |
| Gross margin | % | [71.2%](/filings/0001558370-24-001330.md) | [71.3%](/filings/0001558370-25-001096.md) | [71.1%](/filings/0001104659-26-016380.md) | [74.0%](/filings/0001104659-26-016380.md) | [75.9%](/filings/0001104659-26-016380.md) |
| Operating margin | % | [(0.8%)](/filings/0001558370-24-001330.md) | [(5.2%)](/filings/0001558370-25-001096.md) | [6.6%](/filings/0001104659-26-016380.md) | [7.6%](/filings/0001104659-26-016380.md) | [8.9%](/filings/0001104659-26-016380.md) |
| Net margin | % | [(5.7%)](/filings/0001558370-24-001330.md) | [(7.2%)](/filings/0001558370-25-001096.md) | [10.4%](/filings/0001104659-26-016380.md) | [5.8%](/filings/0001104659-26-016380.md) | [5.8%](/filings/0001104659-26-016380.md) |
| Diluted EPS | $ per share | [(0.60)](/filings/0001558370-24-001330.md) | [(0.89)](/filings/0001558370-25-001096.md) | [1.23](/filings/0001104659-26-016380.md) | [0.70](/filings/0001104659-26-016380.md) | [0.82](/filings/0001104659-26-016380.md) |
| Free cash flow | $m | [0.5](/filings/0001558370-24-001330.md) | [3.4](/filings/0001558370-25-001096.md) | [33.5](/filings/0001104659-26-016380.md) | [38.3](/filings/0001104659-26-016380.md) | [40.4](/filings/0001104659-26-016380.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tcmd/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $56.7m | 1,905,086 |  | Added +125,640 |
| [CADIAN CAPITAL MANAGEMENT, LP](/funds/1423686.md) | 2026-06-30 | $47.0m | 1,576,940 |  | Added +535,868 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $32.5m | 1,092,193 |  | Added +12,477 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $29.2m | 979,340 |  | Reduced −403,472 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $28.9m | 970,246 |  | Added +25,149 |
| [Driehaus Capital Management LLC](/funds/938206.md) | 2026-06-30 | $27.9m | 937,783 |  | Added +195,869 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $21.0m | 706,509 |  | Added +38,175 |
| [FEDERATED HERMES, INC.](/funds/1056288.md) | 2026-06-30 | $20.3m | 681,153 |  | Added +20,196 |
| [ARROWSTREET CAPITAL, LIMITED PARTNERSHIP](/funds/1164508.md) | 2026-06-30 | $19.0m | 638,368 |  | Unchanged |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $17.5m | 586,334 |  | Added +29,540 |

## Recent filings

[All 838 filings](/companies/tcmd/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-10 | 16:06 ET | [10-Q](/filings/0001104659-26-093352.md) | Quarterly report, period 2026-06-30 | 0001104659-26-093352 |
| 2026-08-10 | 16:04 ET | [8-K](/filings/0001104659-26-093346.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-093346 |
| 2026-07-13 | 09:23 ET | [8-K](/filings/0001104659-26-082947.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-082947 |
| 2026-05-07 | 17:06 ET | [8-K](/filings/0001104659-26-057271.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-057271 |
| 2026-05-04 | 16:06 ET | [10-Q](/filings/0001104659-26-054877.md) | Quarterly report, period 2026-03-31 | 0001104659-26-054877 |
| 2026-05-04 | 16:05 ET | [8-K](/filings/0001104659-26-054869.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-054869 |
| 2026-03-25 | 09:00 ET | [DEF 14A](/filings/0001104659-26-034206.md) | Proxy statement, period 2026-05-06 | 0001104659-26-034206 |
| 2026-03-09 | 08:06 ET | [8-K](/filings/0001104659-26-024981.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-024981 |
| 2026-02-17 | 16:06 ET | [10-K](/filings/0001104659-26-016380.md) | Annual report, period 2025-12-31 | 0001104659-26-016380 |
| 2026-02-17 | 16:04 ET | [8-K](/filings/0001104659-26-016370.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-016370 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-016380.md), filed Feb 17, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1a812a7a-e26c-4bcd-994a-3a882536de18)

## About the filer

- CIK: 1027838
- Tickers: TCMD
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: MN
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.